TickerTalks
Browse all tickers →
TickerTalks›$REGN
REREGN

Regeneron Pharmaceuticals, Inc.

Strong FundamentalsStrong FundamentalsRevenue growing 19% YoY at strong marginsStreet coverage with positive forward estimatesConsistent chatter on X (165/wk), no spike
$REGN·$77B·Biotechnology·Healthcare
$790.74-0.7%YTD-2.7%1Y+38.9%
Price updated 4h ago·X counts updated 5d ago
REREGN
$REGNRegeneron Pharmaceuticals, Inc.
$790.74-0.70%165 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $REGN on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

165X posts · last 7 days
Sep 29Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $REGN's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 50% of tracked names.

Bullish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-09-05

Regeneron is set up for an explosive move off the EMAs after a perfect consolidation, and Guggenheim's expanded KT-621 STAT6 map keeps REGN in its Buy stack. Fresh Pfizer data supporting type-2 immunity suppression to improve antitumor response reads through positively for Dupilumab.

Read what X is saying about $REGN

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $REGN — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersWinding up for a moveAI verdict · as of 2026-10-02

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Regeneron at 61% of 52-week range — 15x P/E, Guggenheim Buy on KT-621, Sanofi collaboration extension.

Regeneron Pharmaceuticals is the biotech behind Eylea (anti-VEGF), Dupixent (anti-IL-4/13 for atopic dermatitis/asthma), and growing immuno-oncology franchises. The stock is down 5% YTD, consolidating below the 50-day MA on 1.46x normal volume.

  • The P&L is actually accelerating: revenue grew 19% YoY to $3.6B last quarter at a 24% operating margin and 85% gross margin — the Dupixent franchise is the primary growth engine, with Ubamatamab showing early durable responses in MUC16-expressing tumors.
  • The Sanofi collaboration expansion is a specific commercial anchor — win-win framing that extends Dupixent's economics; Guggenheim's expanded KT-621 STAT6 map keeping REGN in Buy stack is sell-side validation.
  • Officer McCourt's $2M sale at $857 and $850 is a conviction trim; director Guarini's $575K M-Exempt is routine.

Coiling resolves higher if Oct 30 earnings confirm Dupixent growth above 15% YoY and Eylea HD transition continues to work. A soft Dupixent print, or any specific commentary on biosimilar-Eylea competitive pressure, is what breaks the coil lower; a specific Ubamatamab or other oncology pipeline readout plus FY27 revenue guide-up is what breaks it higher.

Agrees with X sentimentX bulls on the explosive-move-off-the-EMAs post-consolidation setup, Guggenheim's expanded KT-621 STAT6 map keeping REGN in Buy, and the Pfizer type-2 immunity data read-through for Dupilumab have the specific setup right — this is a legitimate biotech catalyst story.

What to watch: Oct 30 earnings — Dupixent growth above 15% YoY, Eylea HD transition, Ubamatamab pipeline progression, FY27 revenue guide. A soft Dupixent print or Eylea biosimilar pressure is what breaks the coil lower.

On the calendar: 2026-10-30 — Q3 FY26 earnings

Read the AI verdict on $REGN

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Large biopharma with EYLEA (eye disease), Dupixent (atopic dermatitis/asthma), and a broad antibody pipeline.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $REGN.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $REGN

Neutral — Large biopharma with EYLEA (eye disease), Dupixent (atopic dermatitis/asthma), and a broad antibody pipeline.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+31.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
14.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
8.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
24.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
6.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
4.4Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
14.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
84.5%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 30, 2026$14.29$10.16+40.6%
Q1 2026Apr 29, 2026$9.47$8.91+6.3%
Q4 2025Jan 30, 2026$11.44$10.74+6.5%
Q3 2025Oct 28, 2025$11.83$9.65+22.6%
Next earningsFri, Oct 30·consensus EPS $16.06

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$3.6B+19.0%81.4%17.8%$6.99$848.3M
Q4 FY25$3.9B+2.5%84.9%22.7%$8.21$922.0M
Q3 FY25$3.8B+0.9%86.1%27.3%$14.09$1.4B
Q2 FY25$3.7B+3.6%85.6%29.4%$13.24$967.6M

Forward consensus

5-year forecast · up to 20 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$17.1B$15.6B – $18.1B$54.51$44.56 – $59.8719
FY27$18.6B$16.8B – $20.3B$61.24$47.34 – $68.8217
FY28$19.9B$17.6B – $21.8B$68.43$60.35 – $76.9420
FY29$21.3B$19.0B – $22.9B$75.64$65.00 – $82.9710
FY30$22.4B$20.0B – $24.1B$80.03$68.77 – $87.7910

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.79%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+0.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+8.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 99.1M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.245-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellOct 14Andrew J MurphyCo-Chief Scientific Officer4.1K sh$3.2MSellSep 3Marion MccourtEVP Commercial1.1K sh$970KSellSep 2Kathryn GuariniDirector400 sh$340KSellSep 2Marion MccourtEVP Commercial1.2K sh$1.0MSellAug 10Kathryn GuariniDirector400 sh$320KSellAug 10Huda Y ZoghbiDirector800 sh$640KSellJul 2Arthur F RyanDirector200 sh$130KSellMay 1Arthur F RyanDirector20 sh$14K
+ 9 other (6 exempts · 3 inkinds) in window

See when $REGN insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementOct 68-K — Item 1.01: Material agreement · Item 2.02: Earnings release · Item 8.01: Other event
8-KOfficer or director changeSep 308-K — Item 5.02: Officer or director change
AI summary

REGENERON PHARMACEUTICALS, INC. (REGN) filed an 8-K on 2026-09-30 disclosing a director or executive officer departure, appointment, or compensation change (Item 5.02). No narrative detail was available in the excerpt; this is typically an administrative personnel or governance disclosure with limited market impact unless it involves a key C-suite role.

8-KShareholder voteJun 178-K — Item 5.07: Shareholder vote
AI summary

Regeneron Pharmaceuticals, Inc. held its 2026 annual meeting on June 12, 2026, electing five Class II directors. Joseph Goldstein had the most contested election (72.4M for, 30.9M against); Huda Zoghbi was most broadly supported (100.7M for, 2.7M against). PricewaterhouseCoopers LLP was ratified as auditor (102.5M for, 6.4M against), and executive compensation was approved (96.5M for, 6.9M against). Routine annual governance filing — relatively elevated against-votes for two directors (Goldstein, Christine Poon) merit monitoring but are not unusual for large-cap biotech.

+ 12 other (3 earnings 8-Ks · 2 13Fs · 2 10-Qs · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Here Are Thursday’s Top Wall Street Analyst Research Calls: AngloGold Ashanti, Bank of America, Cirrus Logic, Crocs, Diamondback Energy, Devon Energy, Netflix, PayPal, Spotify Technolgy , and More247wallst.com·2d agoLongleaf Partners Global Fund Q3 2026 Portfolio Reviewseekingalpha.com·2d agoThese 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radarzacks.com·3d agoLongleaf Partners Fund Q3 2026 Portfolio Reviewseekingalpha.com·3d agoThese 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radarzacks.com·4d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport